Akums Drugs and Pharmaceuticals profitability ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
Returns
8.0%8.0%11.1%
5.4%5.4%8.4%
9.7%9.7%9.7%
9.3%8.2%10.4%
Margins
12.6%12.0%11.3%
8.4%8.4%7.6%
—23.4%—
9.5%8.8%8.4%
6.5%5.9%8.4%
6.5%5.9%8.2%
21.8%21.8%4.7%
Additional
31.2%32.9%0.4%
8.0%8.0%11.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AKUMS₹741.05

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAGARWALEYEADVENZYMESAPLLTDAARTIPHARMAARTIDRUGSCORONAHCGMcap ₹11,346 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity11.108.028.02
Return on Assets8.365.365.36
Return on Capital Employed9.669.719.71
Return on Invested Capital10.418.179.32
Margins
EBITDA Margin11.2811.9812.61
Operating Margin7.558.438.43
Incremental Operating Margin—23.43—
Pretax Margin8.388.779.46
Net Income Margin8.355.886.50
Net Income to Common Margin8.215.856.48
FCF Margin4.6821.8121.81
Additional
Effective Tax Rate0.4332.9031.24
Sustainable Growth Rate11.108.028.02
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.